Integrating high-throughput microRNA and mRNA expression data to identify risk mRNA signature for pancreatic cancer

Ping Wang1,2, Weidong Li1,3, Bo Zhai1,3

  • 1The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Insights

This study identifies key messenger RNAs (mRNAs) and microRNAs (miRNAs) for predicting pancreatic cancer outcomes. An optimized mRNA signature shows strong predictive power for clinical use.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Pancreatic cancer has a poor prognosis, necessitating improved prognostic tools.
  • Messenger RNA (mRNA) and microRNA (miRNA) signatures are emerging biomarkers.
  • Integrated analysis of mRNA and miRNA for pancreatic cancer prognosis is lacking.

Purpose of the Study:

  • To identify prognostic mRNA and miRNA signatures in pancreatic cancer.
  • To explore underlying biological mechanisms using enrichment analysis.
  • To develop an optimized prognostic signature for clinical application.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) datasets for mRNA and miRNA identification.
  • Performed enrichment analysis and integrated mRNA-miRNA analysis for subpathways.
  • Employed a random walk algorithm on a global network to identify a prognostic mRNA signature.
  • Validated the signature using an independent testing set.

Main Results:

  • Identified prognostic mRNAs and miRNAs associated with pancreatic cancer.
  • Discovered prognostic subpathways linked to tumor hallmarks, hypoxia, and metabolism.
  • Developed a top mRNA signature with significant predictive power.
  • Confirmed that most genes in the signature are known oncogenes.

Conclusions:

  • Integrated analysis of mRNA and miRNA provides novel insights into pancreatic cancer prognosis.
  • The identified mRNA signature is a promising tool for clinical prognostication.
  • Further optimization enhances the signature's potential for clinical use.